A malaria vaccine has shown promising results in early stage clinical trials, a study suggests.
Researchers found the vaccine, which is being developed in the US, protected 12 out of 15 patients from the disease, when given in high doses.
The method is unusual because it involves injecting live but weakened malaria-causing parasites directly into patients to trigger immunity.
The research is published in the journal Science.
Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institutes of Health, in Maryland, said: “We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers.”
It has been known for several decades that exposure to mosquitoes treated with radiation can protect against malaria.
However, studies have shown that it takes more than 1,000 bites from the insects over time to build up a high level of immunity, making it an impractical method of widespread protection.
Instead, a US biotech company called Sanaria has taken lab-grown mosquitoes, irradiated them and then extracted the malaria-causing parasite (Plasmodium falciparum), all under the sterile conditions.
They are clearly very early stage trials in small numbers of volunteers, but without question we are extremely encouraged by the results”
Dr Ashley BirkettPath Malaria Vaccine Initiative
These living but weakened parasites are then counted and placed in vials, where they can then be injected directly into a patient’s bloodstream. This vaccine candidate is called PfSPZ.
To carry out the Phase-1 clinical trial, the researchers looked at a group of 57 volunteers, none of whom had had malaria before.
Of these, 40 received different doses of the vaccine, while 17 did not. They were then all exposed to the malaria-carrying mosquitoes.
The researchers found that for the participants not given any vaccine, and those given low doses, almost all became infected with malaria.
However for the small group given the highest dosage, only three of the 15 patients became infected after exposure to malaria.
Dr Robert Seder said: “Based on the history, we knew dose was important because you needed 1,000 mosquito bites to get protection – this validates that.
“It allows us in future studies to increase the dose and alter the schedule of the vaccine to further optimise it. The next critical questions will be whether the vaccine is durable over a long period of time and can the vaccine protect against other strains of malaria.”
The Latest on: Malaria vaccine
- Vaccines Market to Reach USD 93.08 billion by 2026, Approval For DENGVAXIA by USFDA to Spur Sales Opportunities, says Fortune Business Insightson December 11, 2019 at 6:54 am
Pune, Dec. 11, 2019 (GLOBE NEWSWIRE) -- The global Vaccines Market size is expected to be USD 93.08 billion by 2026, exhibiting a CAGR of 10.7% during the forecast period. The growing prevalence of ...
- Kenya gets Sh1.2bn to test malaria vaccine on childrenon December 9, 2019 at 4:02 pm
This is the world's first ever malaria vaccine and could be introduced into Kenya's routine immunisation schedule if the pilot finds that to be feasible. • The pilot in Kenya was launched on September ...
- Minestrone Meets Malaria, And Winson December 8, 2019 at 4:22 pm
(Photo by Matt McClain/ The Washington Post via Getty Images) With the vaccine not yet developed, and increasing concerns for anti-malarial ... orchestrated by a parent who happened to be a cell ...
- Soupy Study: Minestrone Could Be A Secret Weapon Against Malariaon December 8, 2019 at 3:00 am
Malaria numbers are going up in some places. There's drug resistance. The vaccine we have isn't very effective," she says. "We need to think outside the box and use more unconventional methods." What ...
- Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain architecture in some Plasmodium falciparum strainson December 6, 2019 at 2:23 am
In malaria-endemic areas, pregnant women commonly suffer from placental malaria (PM ... Several lines of evidence support VAR2CSA as the leading vaccine candidate to prevent PM: parasites isolated ...
- The Gavi coalition boosts the global stockpile of Ebola vaccineson December 5, 2019 at 8:03 am
On a different matter, the Gavi board also agreed to continue support for three pilot projects currently underway in Kenya, Mali and Ghana to see if the world’s first malaria vaccine, RTS,S, is ...
- Gavi Board approves new Ebola vaccine programmeon December 5, 2019 at 6:46 am
Vaccine Alliance will fund a global stockpile of Ebola vaccines and extend support for malaria vaccine pilots New Delhi, 5 December 2019 – A global emergency stockpile of Ebola vaccines will be ...
- WHO urges focus on pregnant women, children to wipe out malariaon December 4, 2019 at 9:03 am
However, it highlighted that three countries—Ghana, Kenya and Malawi—are engaged in clinical trials on the malaria vaccine, which, the report said, had been shown to reduce four in ten malaria cases ...
- Global report shows again that progress against malaria has slowedon December 4, 2019 at 5:59 am
If these measures prove effective, WHO will formulate new policy recommendations. Another key component in the fight against malaria would be a vaccine. In 2019, three African countries introduced the ...
- Malaria killed 405,000 in 2018 as medical funding stalled: WHOon December 3, 2019 at 8:42 pm
In November, Science Magazine reported that the first malaria vaccine was rolled out in Malawi, Ghana and Kenya. Meanwhile, it was reported last November that a United Nations peacekeeper from China ...
via Google News and Bing News